On April 30, 2024 BetaGlue Technologies S.p.A. ("BetaGlue" or the "Company") a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers reported the name change to BetaGlue Therapeutics, the new trading name of the Company, and also a new brand identity.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alongside this, the Company also announces Yntradose, BetaGlue’s radiotherapy platform, comprising four key product components; YntraDose-90, YntraDose-Guide, YntraDose-Glue and YntraDose-Deliver. Read more about YntraDose, here). The product was formerly called BAT-90.
The Company worked in collaboration with Cohesion Labs to deliver a new website and complete rebrand of the Company and its products.
BetaGlue’s CEO, Dr. Colin Story commented: "The rebrand is a result of a thorough and diligent process undertaken by our team and the team at Cohesion Labs. We now have a company name, product name, website and visual identity that is reflective of who we are and how our unique platform technology has the potential to provide a new standard-of-care for a wide range of solid tumour cancer patients."
Speaking about the brand, CEO of UK based creative agency, Cohesion Labs, Craig Stockwell said: "Collaborating with companies that impact patient outcomes, like BetaGlue, is truly rewarding. Their dedication in bringing ground-breaking precision radiotherapy treatments to patients was evident from our first conversation, inspiring us to create a brand that reflects that ambition."
(Press release, BetaGlue Therapeutics, APR 30, 2024, View Source [SID1234661236])